Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asger Lund

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Frontiers in Endocrinology|January 25, 2021
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver FatDavid S Mathiesen, Asger Lund, Tina Vilsbøll, et al.
Diabetologia|June 1, 2014
Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individualsJonatan I Bagger, Filip K Knop, Asger Lund, et al.
JOP : Journal of the Pancreas|September 7, 2010
The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiencyFilip K Knop, Tina Vilsbøll, Asger Lund, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 22, 2021
Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinicKatrine B Hansen, Mathilde Svendstrup, Asger Lund, et al.
BMC Research Notes|June 3, 2014
Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case reportFilip K Knop, Asger Lund, Sten Madsbad, et al.
Endocrine Connections|October 4, 2014
On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetesDavid P Sonne, Asger Lund, Jens Faber, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2011
Impaired regulation of the incretin effect in patients with type 2 diabetesJonatan I Bagger, Filip K Knop, Asger Lund, et al.
BMJ Open|June 29, 2018
Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trialNicklas Järvelä Johansen, Thomas Fremming Dejgaard, Asger Lund, et al.
Pancreas|June 1, 2012
Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetesMorten Hansen, Anders Rinnov Nielsen, Tina Vilsbøll, et al.
European Journal of Endocrinology|March 30, 2022
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacologyDavid S Mathiesen, Asger Lund, Jens J Holst, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Frontiers in Endocrinology|January 25, 2021
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver FatDavid S Mathiesen, Asger Lund, Tina Vilsbøll, et al.
Diabetologia|June 1, 2014
Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individualsJonatan I Bagger, Filip K Knop, Asger Lund, et al.
JOP : Journal of the Pancreas|September 7, 2010
The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiencyFilip K Knop, Tina Vilsbøll, Asger Lund, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 22, 2021
Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinicKatrine B Hansen, Mathilde Svendstrup, Asger Lund, et al.
BMC Research Notes|June 3, 2014
Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case reportFilip K Knop, Asger Lund, Sten Madsbad, et al.
Endocrine Connections|October 4, 2014
On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetesDavid P Sonne, Asger Lund, Jens Faber, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2011
Impaired regulation of the incretin effect in patients with type 2 diabetesJonatan I Bagger, Filip K Knop, Asger Lund, et al.
BMJ Open|June 29, 2018
Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trialNicklas Järvelä Johansen, Thomas Fremming Dejgaard, Asger Lund, et al.
Pancreas|June 1, 2012
Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetesMorten Hansen, Anders Rinnov Nielsen, Tina Vilsbøll, et al.
European Journal of Endocrinology|March 30, 2022
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacologyDavid S Mathiesen, Asger Lund, Jens J Holst, et al.
Pageof 6